Emtricitabine/rilpivirine/tenofovir

From Wikipedia, the free encyclopedia
Emtricitabine/rilpivirine/tenofovir
Combination of
Emtricitabine Nucleoside analog reverse-transcriptase inhibitor
Rilpivirine Non-nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil fumarate Nucleoside analog reverse-transcriptase inhibitor
Clinical data
Legal status ℞-only (US) ℞ Prescription only
Routes Oral
Identifiers
ATC code J05AR08
 YesY (what is this?)  (verify)

Emtricitabine/rilpivirine/tenofovir (trade name Complera, Eviplera) is a fixed dose combination of antiretroviral drugs for the treatment of HIV.[1] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011 (Eviplera),[2] for patients who have not previously been treated for HIV.[3] It is available as a once-a-day single tablet.

References

  1. ↑ "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". Food and Drug Administration. August 10, 2011. 
  2. ↑ "Eviplera; summary of the European public assessment report". European Medicines Agency. November 2011. 
  3. ↑ "FDA approves Gilead-J&J HIV pill Complera". Business Week. August 10, 2011. 


Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Entry/fusion inhibitors
(Discovery & development)
  • gp41 (Enfuvirtide)
  • CCR5 (Maraviroc
  • Vicriviroc†, Cenicriviroc†, PRO 140†)
  • CD4 (Ibalizumab†)
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside &
nucleotide (NRTI)
  • Nucleoside analogues/NARTIs: Abacavir (ABC)°#
  • Emtricitabine (FTC)°#
  • Lamivudine (3TC)°#
  • Didanosine (ddI)#
  • Zidovudine (AZT)#
  • Apricitabine†
  • Stampidine†
  • Elvucitabine†
  • Racivir†
  • Amdoxovir†
  • Stavudine (d4T)#
  • Zalcitabine (ddC)◊
  • Festinavir† 
  • Nucleotide analogues/NtRTIs: Tenofovir disoproxil fumarate (TDF)°#
  • Tenofovir alafenamide fumarate (TAF)†
Non-nucleoside (NNRTI)
(Discovery & development)
  • (1st generation) Efavirenz (EFV)°#
  • Nevirapine (NVP)#
  • Loviride◊
  • Delavirdine (DLV)◊

  • (2nd generation) diarylpyrimidines (Etravirine
  • Rilpivirine)
  • Lersivirine†
Integrase inhibitors
  • Raltegravir°
  • Elvitegravir
  • Dolutegravir
  • Globoidnan A (experimental)
  • MK-2048†
  • BI 224436†
  • GSK744†  
Maturation inhibitors
  • Bevirimat†
Protease Inhibitors (PI)
(Discovery and development)
1st generation
  • Fosamprenavir°
  • Lopinavir°#
  • Nelfinavir#
  • Ritonavir#
  • Saquinavir#
  • Amprenavir◊
  • Indinavir◊#
2nd generation
  • Atazanavir°
  • Darunavir°
  • Tipranavir 
Combined formulations
  • Lamivudine/zidovudine
  • Emtricitabine/tenofovir/efavirenz
  • Abacavir/lamivudine/zidovudine
  • Tenofovir/emtricitabine
  • Lopinavir/ritonavir
  • Abacavir/lamivudine
  • Emtricitabine/rilpivirine/tenofovir
  • Elvitegravir/cobicistat/emtricitabine/tenofovir
Experimental agents
Uncoating inhibitors
  • TRIM5alpha (gene)
Transcription inhibitors
  • Tat antagonists
Translation inhibitors
  • Trichosanthin
Other
  • Abzyme
  • Calanolide A
  • Ceragenin
  • Cyanovirin-N
  • Diarylpyrimidines
  • Epigallocatechin gallate (EGCG)
  • Foscarnet
  • Griffithsin
  • Hydroxycarbamide
  • Miltefosine
  • Portmanteau inhibitors
  • Seliciclib†
  • Synergistic enhancers
  • Tre recombinase
  • Zinc finger protein transcription factor
  • KP-1461†
  • Cobicistat†
Failed agents
  • Dexelvucitabine
  • Capravirine
  • Emivirine
  • Lodenosine
  • Atevirdine
  • Brecanavir
  • Aplaviroc
  • #WHO-EM
  • ‡Withdrawn from market
  • Clinical trials:
    • †Phase III
    • §Never to phase III
°DHHS preferred first-line agent. ◊Formerly or rarely used agent.

M: VIR

virs(prot)/clss

cutn/syst (hppv/hiva, infl/zost/zoon)/epon

drug (dnaa, rnaa, rtva, vacc)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.